title: Unrelated donor bone marrow transplantation for 100 pediatric patients: a single institute's experience.
abstract: In all, 100 unrelated donor bone marrow transplantations (UD-BMT) were performed in our institute between October 1993 and January 2003. Of 93 evaluable patients, 73 patients had hematological malignancy, 13 had nonmalignancy and seven had lymphoproliferative disease. The estimated 9-year event-free survival (EFS) rate was 57.1+/-5.5% in all patients. In the following analyses of the patients with hematological malignancy, the standard group had significantly better EFS than the high-risk group (61.5+/-7.0 vs 35.6+/-9.7%, P=0.02), and the EFS rate of the tacrolimus (FK-506)+methotrexate (MTX)+/-methylprednisolone prophylactic group for graft-versus-host disease was superior to that of the FK-506 without MTX group (75.7+/-8.0 vs 55.8+/-7.6%, P=0.02). When we compared the EFS rates of the FK506+MTX+/-methylprednisolone (mPSL) group and the HLA-matched related donor BMT group in our institute, these were almost similar (75.7+/-8.1 vs 68.4+/-9.3%). Therefore, UD-BMT using FK-506+MTX+/-mPSL is a safe and useful method for children with hematological malignancy who require allogeneic BMT.
authors.affiliation: Department of Pediatrics, Osaka General Medical Center, Osaka, Japan. yagikei@gh.pref.osaka.jp
authors.forename: K
authors.initials: K
authors.lastname: Yumura-Yagi
authors.forename: M
authors.initials: M
authors.lastname: Inoue
authors.forename: N
authors.initials: N
authors.lastname: Sakata
authors.forename: T
authors.initials: T
authors.lastname: Okamura
authors.forename: M
authors.initials: M
authors.lastname: Yasui
authors.forename: A
authors.initials: A
authors.lastname: Sawada
authors.forename: E
authors.initials: E
authors.lastname: Sato
authors.forename: K
authors.initials: K
authors.lastname: Chayama
authors.forename: C
authors.initials: C
authors.lastname: Endo
authors.forename: M
authors.initials: M
authors.lastname: Sasabe
authors.forename: T
authors.initials: T
authors.lastname: Miyamura
authors.forename: Y-D
authors.initials: YD
authors.lastname: Park
authors.forename: T
authors.initials: T
authors.lastname: Nakano
authors.forename: J
authors.initials: J
authors.lastname: Inagaki
authors.forename: T
authors.initials: T
authors.lastname: Kishimoto
authors.forename: K
authors.initials: K
authors.lastname: Nomura
authors.forename: I
authors.initials: I
authors.lastname: Saito
authors.forename: S
authors.initials: S
authors.lastname: Hamada
authors.forename: T
authors.initials: T
authors.lastname: Nakano
authors.forename: Y
authors.initials: Y
authors.lastname: Hashii
authors.forename: K
authors.initials: K
authors.lastname: Kawa
mesh_terms: D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000276:immunology / Q000379:methods* / Q000401:mortality; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection / Q000209:etiology; D006086:Graft vs Host Disease / Q000139:chemically induced / Q000209:etiology / Q000517:prevention & control; D006402:Hematologic Diseases / Q000150:complications / Q000401:mortality / Q000628:therapy; D006801:Humans; D007223:Infant; D007564:Japan; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008775:Methylprednisolone / Q000627:therapeutic use; D011292:Premedication; D012189:Retrospective Studies; D016559:Tacrolimus / Q000627:therapeutic use / Q000633:toxicity; D014019:Tissue Donors
chemical_list: D016559:Tacrolimus; D008775:Methylprednisolone; D008727:Methotrexate